摘要
目的研究bcl-2和乳腺癌耐药蛋白(BCRP)基因在非霍奇金淋巴瘤(NHL)中的表达及其相关性。方法对初治弥漫大B细胞淋巴瘤(DLBCL)患者(40例)淋巴结组织液,采用流式细胞术(FCM)及反转录聚合酶链反应(RT—PCR)技术定量检测其BCRPmRNA的表达,同时将患者标本常规石蜡包埋、HE染色和链霉菌素生物素技术(LSAB)免疫组织化学法标记bcl-2蛋白表达。结果40例DLBLC患者的bcl-2与BCRP的阳性表达率分别为60.0%(24/40),37.5%(15/40),不同临床分期的DLBCL患者,BCRP阳性表达率差异有统计学意义(χ2=6.0606,P〈0.05)。bcl-2、BCRP表达阳性组有效率低于表达阴性组,差异有统计学意义(χ2=5.7618,P〈0.05;χ2=6.5541,P〈0.05);bcl-2和BCRP表达均阳性与均阴性患者的疗效比较,差异无统计学意义(χ2=2.0263,P〉0.05)。结论BCRP可能在DLBCL的原发多药耐药中发挥重要作用,并有助于化疗疗效的评估及提示疾病转归;bcl-2在DLBCL中的表达对肿瘤恶性程度及预后的判断均有一定意义;联合检测bcl=2和BCRP基因对评价DLBCL预后有较大意义。
Objective To explore the expression of b-cell lymphoma/leukemia-2 (bcl-2) and breast cancer drug-resistant protein (BCRP) in diffuse large B cell lymphoma (DLBCL) and their correlation. Methods Using flow cytometry (FCM) and semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) assay the expressions of BCRP gene was analysed in 40 DLBCL samples, bcl-2 protein were measured by immunohistoehemistry on paraffin-embedded slices in 40 cases of DLBCL. Results The positive expression rate of bcl-2 and BCRP protein were 60,0 % (24/40) and 37.5 % (15/40) in 40 patients with DLBCL respectively. There was significant differences between positive group and negative groups (χ2= 5.7618, P 〈0.05; )χ2 = 6.5541, P 〈0.05). There was no significant correlation between Bcl-2 and BCRP gene in effective treatment group and therapies group or progress group (χ2 = 2.0263, P 〉0.05). Conclusion BCRP may play an important role in DLBCL primay much medicine drug-resistant, thus it may be a useful prediction of chemotherapeutic treatment and risk of relapse. The level bcl-2 expression was closely related with the grade of malignancy and the prognosis of DLBCL. There was no significant correlation between bcl-2 and BCRP gene. The detection of bcl-2 and BCRP gene played an important role in evaluating DLBCL outcome.
出处
《白血病.淋巴瘤》
CAS
2011年第6期373-375,共3页
Journal of Leukemia & Lymphoma